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Recently in Nature, Jaskelioff et al. (2010) demonstrated that multiple aging phenotypes in a mouse model of
accelerated telomere loss can be reversed within 4 weeks of reactivating telomerase. This raises the major
question of whether physiological aging, likely caused by a combination of molecular defects, may also be
reversible.Accumulation of short/damaged telo-
meres with increasing age is considered
one of the main sources of aging-associ-
ated DNA damage responsible for the
loss of regenerative potential in tissues
and during systemic organismal aging
(Harley et al., 1990; Flores et al., 2005).
Mounting evidence suggests that telome-
rase is a longevity gene that functions
by counteracting telomere attrition. Thus,
telomerase-deficient mice age prema-
turely, and telomerase overexpression
results in extended longevity in mice
(Tomas-Loba et al., 2008). Moreover,
human mutations in telomerase compo-
nents produce premature adult stem cell
dysfunction and decreased longevity
(Mitchell et al., 1999).
Previous work had shown that restora-
tion of telomerase activity in mouse
zygotes with critically short telomeres,
owing to a deficiency in the
telomerase RNA component
(Terc), rescues critically short
telomeres and chromosomal
instability in the resulting
mice (Samper et al., 2001).
Restoration of telomerase
activity in zygotes also pre-
vented the wide range of
degenerative pathologies
that would otherwise appear
in telomerase-deficient mice
with critically short telomeres,
including bone marrow apla-
sia, intestinal atrophy, male
germ line depletion, and
adult stem cell dysfunction
(Samper et al., 2001; Siegl-
Cachedenier et al., 2007),
and resulted in a normal
organismal life-span (Siegl-
Cachedenier et al., 2007).
Together, all the above find-
ings indicate that aging provoked by crit-
ical telomere shortening can be prevented
or delayed by telomerase reactivation.
From these grounds, reversion of aging
caused by telomere loss was the next
frontier. A recent study in Nature takes
an important step forward from these
previous findings by using a new mouse
model for telomerase deficiency, de-
signed to permit telomerase reactivation
in adultmice after telomere-induced aging
phenotypes have been established (Jas-
kelioff et al., 2010). Specifically, DePinho
and colleagues generated a knockin allele
encoding a 4-OH tamoxifen (4-OHT)-
inducible mouse telomerase (TERT-ER)
under the control of the TERT endogenous
promoter. In the absence of tamoxifen,
these mice exhibit premature appearance
of aging pathologies and reduction in
survival (Figure 1). Thesemice phenocopy
previously described Terc-deficient mice,
which highlights that elongation of short
telomeres by telomerase is the main
mechanism by which telomerase protects
from aging pathologies. Importantly,
4 weeks of tamoxifen treatment to induce
TERT re-expression in adult TERT-ER
mice with clear signs of premature
aging was sufficient to extend their
telomeres and rescue telomeric DNA
damage signaling and associated check-
point responses. Dramatically, tamox-
ifen-induced TERT re-expression also
led to resumption of proliferation in quies-
cent cultured cells and eliminated the
degenerative phenotypes across multiple
organs, including testis, spleen, and intes-
tines (Figure 1). Reactivation of telome-
rase also ameliorated the decreased
survival of TERT-ER mice. These findings
represent an important advance in the
aging field, as they show that
aging induced by telomere
loss can be reversed in
a broad range of tissues and
cell types, including neuronal
function.
Looking to the future, the
next key question is to what
extent natural, physiological
aging is caused by the pres-
ence of critically short telo-
meres and, consequently, to
what extent telomere restora-
tion will be able to reverse
physiological aging. In this re-
gard, other recent findings
support the idea that telomere
shortening does impact
natural mouse aging. On one
hand, despite the long-
standing belief that mouse
aging was not linked to telo-
mere shortening given that
Figure 1. Antiaging Effects of Telomerase
Schematic showing the major findings of Jaskelioff et al. (2010). Telomerase
reactivation in late generation telomerase-deficient mice (G4TERT-ER) could
revert some of the aging phenotypes observed, demonstrating the regenera-
tive potential capacity of different tissues.Cell Stem Cell 8, January 7, 2011 ª2011 Elsevier Inc. 3
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Previewsmice are born with very long telomeres—
much longer than human telomeres—
mouse telomeres do suffer extensive
shortening associated with aging (Flores
et al., 2008). Inparticular,whilemousecells
maintain relatively long telomeres during
their first year of life, there is a dramatic
loss of telomeric sequences at 2 years of
age, even in various stem cell populations,
and this change is concomitant with the
loss of regenerative capacity associated
with mouse aging. In addition, telome-
rase-deficient mice from the first genera-
tion (G1Terc/) exhibit a significant
decrease in median and maximum
longevity and a higher incidence of age-
related pathologies and stem cell dysfunc-
tion compared with wild-type mice (Flores
et al., 2005; Garcia-Cao et al., 2006), indi-
cating that, as in humans, telomerase
activity is rate limiting for natural mouse
longevity and aging. These results suggest
that strategies aimed to increase telome-
rase activity may delay natural mouse
aging. Further supporting this notion, it
was recently shown that overexpression
of TERT in the context of mice engineered
to be cancer resistant owe to increaseHGPS-Derived iPS
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Some problems in biology are more
difficult to study than others. Human
aging is certainly one of them. Most
conclusions regarding molecular mecha-
nism of human aging rely onmere correla-
tion, and direct experimental testing
is generally not feasible. One approach
to dissect the molecular basis of human
aging is to study naturally occurring
premature aging disorders. One of the
most dramatic and prominent of such
4 Cell Stem Cell 8, January 7, 2011 ª2011 Eexpression of tumor suppressor genes
(Sp53/Sp16/SARF/TgTERT mice) was
sufficient to decrease telomere damage
with age, delay aging, and increasemedian
longevity by 40% (Tomas-Loba et al.,
2008). However, it remains to be seen
whether telomerase reactivation late in life
would be sufficient to delay natural mouse
aging and extend mouse longevity without
increasing cancer incidence.
In summary, these proof-of-principle
studies using genetically modified mice
are likely to encourage the development
of targeted therapeutic strategies based
on reactivation of telomerase function.
Indeed, small molecule telomerase acti-
vators have been reported recently and
have demonstrated some preliminary
health-span beneficial effects in humans
(Harley et al., 2010). Identifying drugable
targets and candidate activators clearly
opens a new window for the treatment of
age-associated degenerative diseases.
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leads to the development of highly diverse
symptoms ranging from depletion of
subcutaneous fat to loss of hair and
tendon contractures. The diversity of
affected tissues pointed early on to stem
cell defects as a likely disease mecha-
nism. Most relevant in patients are
vascular defects and recurring strokes,
which invariably are fatal in patients in
their mid- to late teens (Hennekam,
2006). The disease is exceedingly rare
